1.Adjuvant treatment of Stage III colon cancer after complete resection of the primary tumor. 2.Treatment of advanced colorectal cancer. 3.Usually used in combination with fluorouracil (5-FU) and leucovorin.

Antineoplastic Drugs

1.Administration: Intravenous infusion. 2.Distribution: Platinum rapidly binds to plasma proteins and erythrocytes. 3.Metabolism: Non-enzymatic biotransformation to active platinum complexes. 4.Elimination: Mainly via renal excretion. 5.Half-life: Multi-phase elimination with a prolonged terminal phase due to tissue binding.

History of hypersensitivity reactions to oxaliplatin or other platinum-based drugs (e.g., cisplatin, carboplatin).

1.Not assigned under the newer FDA labeling system. 2.Risk summary: May cause fetal harm based on its DNA-damaging mechanism and animal studies.

Breastfeeding is not recommended during treatment and for 3 months after the last dose, due to potential serious adverse reactions in breastfed infants.

Most common adverse reactions (?40% incidence): 1.Peripheral sensory neuropathy 2.Neutropenia 3.Thrombocytopenia 4.Anemia 5.Nausea and vomiting 6.Diarrhea 7.Fatigue 8.Stomatitis 9.Elevated liver enzymes (AST/ALT, ALP) 10.Oxaliplatin Serious adverse effects include: 1.Anaphylaxis / hypersensitivity reactions 2.Myelosuppression 3.Pulmonary toxicity 4.Posterior reversible encephalopathy syndrome (PRES) 5.QT interval prolongation 6.Rhabdomyolysis

Standard regimen (FOLFOX regimen): 1.Oxaliplatin: 85 mg/m2 IV infusion over 120 minutes, every 2 weeks 2.Given concurrently with leucovorin, followed by fluorouracil (5-FU). Treatment duration: 1.Adjuvant therapy: up to 12 cycles 2.Advanced colorectal cancer: until disease progression or unacceptable toxicity.

Safety and efficacy in pediatric patients have not been established. Clinical trials in children showed sensory neuropathy as the dose-limiting toxicity.

Severe renal impairment (CrCl <30 mL/min):Reduce dose to 65 mg/m2.

1.No specific dose adjustment recommended. 2.Monitor liver function tests regularly due to risk of hepatotoxicity.

1.Dilute with 5% dextrose solution only (not saline). 2.Diluted solution stability: (1)6 hours at room temperature (20–25°C) (2)24 hours refrigerated (2–8°C) (3)Protect concentrate from light and do not freeze.